期刊
PPAR RESEARCH
卷 2008, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2008/247379
关键词
-
资金
- National Institutes of Health
- Sankyo Co.
- Charlotte Geyer Foundation
PPAR gamma and PPAR delta agonists represent unique classes of drugs that act through their ability to modulate gene transcription associated with intermediary metabolism, differentiation, tumor suppression, and in some instances proliferation and cell adhesion. PPAR gamma agonists are used by millions of people each year to treat type 2 diabetes but may also find additional utility as relatively nontoxic potentiators of chemotherapy. PPAR delta agonists produce complex actions as shown by their tumor promoting effects in rodents and their cholesterol-lowering action in dyslipidemias. There is now emerging evidence that PPARs regulate tumor suppressor genes and developmental pathways associated with transformation and cell fate determination. This review discusses the role of PPAR gamma and PPAR delta agonists as modulators of these processes. Copyright (C) 2008 Robert I. Glazer et al.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据